Abstract
We conducted a feasibility study using S-1, a novel oral derivative of 5-fluorouracil, as postoperative adjuvant chemotherapy for curatively resected gastric cancer patients. Adjuvant chemotherapy consisted of eight courses (4-week administration and 2-week withdrawal) of S-1, at 80-120 mg/body per day. Forty-one patients from 11 institutions were enrolled in this pilot study, from November 1999 to October 2000. Thirty-five patients were eligible. In 7 patients, S-1 administration was discontinued due to recurrence. Among the 28 patients without recurrence, the planned eight courses of S-1 were administered to 17 patients (60.7%). In 4 patients, S-1 administration was discontinued due to subjective symptoms, such as anorexia, in the first course. Adverse reactions such as neutropenia, leukopenia, elevated total bilirubin, anorexia, general fatigue, diarrhea, nausea, and stomatitis were seen in more than half of the patients. Although grade 3 neutropenia (29.3%), leukopenia (9.8%), and diarrhea (9.8%) were observed, no grade 4 adverse effects appeared. Compared with the treatment of unresectable or recurrent gastric cancer with S-1, the incidence of adverse reactions in the adjuvant setting was slightly higher, probably due to t...Continue Reading
Citations
Aug 11, 2007·Cancer Chemotherapy and Pharmacology·Mitsugu KochiTadatoshi Takayama
Aug 7, 2012·Cancer Chemotherapy and Pharmacology·Jae Ho JeongYoon-Koo Kang
May 23, 2012·Langenbeck's Archives of Surgery·Nobuyuki TakemuraToshiharu Yamaguchi
Mar 29, 2006·Journal of Gastroenterology·Yasuo KogaKohji Miyazaki
Sep 8, 2010·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Yasuhiro KoderaUNKNOWN Chubu Clinical Cancer Group
Feb 18, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Satoru IwasaYasuhiro Shimada
Sep 4, 2008·Current Oncology Reports·Takeshi Sano
Nov 6, 2007·The New England Journal of Medicine·Shinichi SakuramotoUNKNOWN ACTS-GC Group
Jul 1, 2009·Annals of Surgical Oncology·Eiji OkiYoshihiko Maehara
Dec 18, 2012·Annals of Surgical Oncology·Toru AoyamaAkira Tsuburaya
Apr 20, 2013·World Journal of Gastroenterology : WJG·Lei ChenYu-Xin Chen
Apr 10, 2010·World Journal of Surgery·Seiji ItoYoshitaka Yamamura
Mar 20, 2012·Clinical Lung Cancer·Tomoshi TsuchiyaYoshitaka Taniguchi
May 5, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Tokujiro YanoUNKNOWN Lung Oncology Group in Kyushu (LOGIK)
Aug 9, 2007·Cancer Science·Woo Young KimKosei Hirakawa
Mar 31, 2009·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Y KoderaUNKNOWN Chubu Clinical Oncology Group
Apr 18, 2015·BMC Cancer·Takashi ShigekawaToshiaki Saeki
Dec 7, 2016·International Journal of Clinical Oncology·Norihito OkumuraHiroshi Date
Mar 26, 2008·British Journal of Cancer·T Kubota
Sep 29, 2005·British Journal of Cancer·M TsukudaUNKNOWN Chemotherapy Study Group of Head and Neck Cancer
Mar 22, 2006·Anti-cancer Drugs·Yuko TsuruokaTetsuhiko Shirasaka
Jun 29, 2006·Japanese Journal of Clinical Oncology·Yuji UedaUNKNOWN Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC)
Sep 19, 2014·World Journal of Gastroenterology : WJG·Jun NakamuraKohji Miyazaki
Jul 11, 2019·Investigational New Drugs·Kenichi InoueUNKNOWN SBCCSG-14 investigators
Jul 25, 2020·BMC Cancer·Osamu ItanoYuko Kitagawa
May 11, 2017·International Journal of Clinical Oncology·Takuma OhashiEigo Otsuji
Aug 31, 2017·BMC Cancer·Yoshinobu HataAkira Iyoda
Oct 11, 2019·JAMA Oncology·David H IlsonKohei Shitara
Apr 19, 2021·World Journal of Surgical Oncology·Hung-Hsuan YenI-Rue Lai